Announced Sat, 31 May · 01:12 IST

Intimation of re-appointment of Secretarial Auditor, Internal Auditor and Cost Auditor.

Management Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Fredun Pharmaceuticals has informed the stock exchange that its Board, at a meeting on May 30, 2025, approved three auditor appointments. M/s. Kala Agarwal, a Practicing Company Secretary from Mumbai, has been appointed as Secretarial Auditor for a five-year term covering FY 2025-26 to FY 2029-30, subject to shareholder approval. M/s. Nikhil Maniar & Associates, Chartered Accountants, has been appointed as Internal Auditor for FY 2025-26. M/s. Joshi Apte & Associates, Practising Cost Accountants, has been appointed as Cost Auditor for FY 2025-26. All three appointments are standard compliance requirements under the Companies Act, 2013 and SEBI Listing Regulations.

Likely market impact

This is a routine regulatory compliance filing with no material impact on the company's operations or shareholders. No red flags or governance concerns are evident; the company is simply meeting its annual audit appointment obligations.